Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the irritation potential of HG22
RBR-57b63dPhase 1Not yet recruiting
- Sponsor
- Infinant Health
- Start
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Infinant Health. Planned start Aug 2022; status: not yet recruiting.
Beyond the preview
Go deeper on RBR-57b63d.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-57b63d.